If You Invested in Tenon Medical (TNONW)

Tenon Medical, Inc. is a medical device company in the surgical and medical instruments and apparatus sector. According to available information, the company has developed a novel, minimally invasive approach to the sacroiliac (SI) joint using a single titanium implant for the treatment of common SI joint disorders that can cause lower back pain. Its business is centered on addressing SI joint conditions through a specialized implant system.

The company’s commercial focus includes three main opportunities related to SI joint procedures. These are primary SI joint procedures, revision procedures for failed SI joint implants, and SI joint fusion used as an adjunct to a spine fusion construct. Tenon Medical states that it derives most of its revenue from sales of its Catamaran System to a limited number of clinicians, indicating a targeted clinical user base for its device.

Tenon Medical, Inc. is identified in SEC filings as a Delaware corporation. The filings also indicate that the company is an emerging growth company under applicable U.S. securities regulations. Its warrants trade on The Nasdaq Stock Market LLC under the symbol TNONW, as disclosed in an 8-K filing. The same filing lists Tenon Medical, Inc. as the registrant and confirms that it files reports with the U.S. Securities and Exchange Commission.

According to an 8-K describing its annual meeting of stockholders, Tenon Medical, Inc. held its 2025 Annual Meeting of Stockholders virtually. The filing describes matters submitted to a vote of stockholders, including the election of directors, approval of the exercisability of certain warrants, amendments to the company’s 2022 Equity Incentive Plan, and ratification of the selection of an independent auditor. These details highlight that Tenon Medical uses equity-based compensation plans and warrant structures as part of its capital and incentive framework.

The 8-K filing also notes that Tenon Medical, Inc. had outstanding common stock and preferred stock that constituted its voting securities as of a specified record date for the annual meeting. The company’s board of directors adjusted the record date when prior meeting sessions were adjourned due to the absence of a quorum, illustrating the procedural steps it takes to complete required corporate governance actions.

From the same filing, it is evident that Tenon Medical’s stockholders voted on the exercisability of Series C-1 and Series C-2 warrants to purchase shares of common stock at a specified exercise price for defined terms following stockholder approval. Stockholders also approved amendments to the 2022 Equity Incentive Plan to increase the number of shares reserved for issuance and to modify the plan’s evergreen provision, subject to limits based on a percentage of outstanding common stock. These actions show that Tenon Medical, Inc. actively manages its equity plans and capital structure through stockholder approvals.

Tenon Medical’s focus on a minimally invasive SI joint implant and related procedures places it within a specialized area of the medical device industry. Its emphasis on primary SI joint procedures, revision procedures for failed SI joint implants, and SI joint fusion adjunct to spine fusion constructs defines the core of its product and procedure strategy as described in available information.

Business Focus and Product Approach

Tenon Medical, Inc. describes itself as having developed a minimally invasive approach to the SI joint using a single, robust titanium implant. The company’s Catamaran System is identified as the source of most of its revenue, with sales concentrated among a limited number of clinicians. This suggests a focused commercialization strategy around a specific device platform for SI joint disorders.

The company’s stated commercial opportunities—primary SI joint procedures, revision procedures of failed SI joint implants, and SI joint fusion adjunct to a spine fusion construct—indicate that its technology is intended to be used both in initial SI joint interventions and in follow-up or adjunctive procedures where SI joint fusion is part of a broader spine treatment plan.

Capital Structure and Corporate Governance

In the 8-K describing its 2025 Annual Meeting of Stockholders, Tenon Medical, Inc. reports that it had common stock and multiple series of preferred stock outstanding, each with defined voting rights. The filing details the number of shares represented in person or by proxy and confirms that a quorum was present under Delaware law and the company’s bylaws. This demonstrates that the company follows formal stockholder voting procedures for key corporate matters.

The same filing outlines the election of seven director nominees to serve until the company’s next annual meeting or until their successors are duly elected and qualified, or until earlier resignation, death, or removal. It also notes that directors are elected by a plurality of the votes cast, meaning votes could be cast in favor of or withheld from nominees, with no votes against applicable in that context.

Stockholders voted on a proposal to approve the exercisability of warrants issued in a warrant exercise inducement transaction, including Series C-1 and Series C-2 Warrants. The proposal required the affirmative vote of the holders of a majority of the shares represented at the annual meeting and entitled to vote, and the filing states that the proposal was approved. This indicates that Tenon Medical, Inc. uses warrant structures that require stockholder approval for exercisability under certain conditions.

Another proposal described in the filing involved amendments to the Tenon Medical, Inc. 2022 Equity Incentive Plan. The amendments included increasing the number of shares of common stock reserved for issuance under the plan and changing the plan’s evergreen provision, which governs automatic annual increases in the share reserve based on a percentage of outstanding common stock or a lesser number determined by the plan administrator. Stockholders approved this proposal as well, based on the voting results reported in the 8-K.

Finally, stockholders ratified the selection of Haskell & White LLP as Tenon Medical’s independent auditor for the fiscal year ending on a stated date. The proposal required the affirmative vote of the holders of a majority of the shares represented at the annual meeting and entitled to vote, and the filing notes that the proposal was approved. This reflects the company’s process for obtaining stockholder ratification of its independent auditing firm.

Listing and Security Information

According to the 8-K, Tenon Medical, Inc.’s warrants are listed on The Nasdaq Stock Market LLC under the symbol TNONW. The filing identifies Tenon Medical, Inc. as the registrant and confirms that it is an emerging growth company as defined in U.S. securities regulations. The company indicates whether it has elected not to use the extended transition period for complying with new or revised financial accounting standards, as permitted for emerging growth companies.

The filing also includes standard disclosures regarding whether the filing is intended to satisfy certain communications provisions under the Securities Act and the Exchange Act, with check boxes indicating that it is not being used for written communications under Rule 425, soliciting material under Rule 14a-12, or pre-commencement communications under specified tender offer or issuer bid rules. These disclosures are part of the company’s compliance with SEC reporting requirements.

Use of Equity Incentives and Warrants

Tenon Medical, Inc.’s 8-K provides detail on its use of equity-based incentives and warrants. The 2022 Equity Incentive Plan, as amended, reserves a specified number of shares of common stock for issuance and includes an evergreen provision that allows for annual increases in the share reserve based on a percentage of outstanding common stock or a lesser amount determined by the plan administrator. This structure allows the company to grant equity awards over time while maintaining stockholder-approved limits.

The warrant-related proposal described in the filing concerns the exercisability of Series C-1 and Series C-2 Warrants issued in a warrant exercise inducement transaction. The filing states that the Series C-1 Warrants will become exercisable for five years and the Series C-2 Warrants for three years from the date stockholder approval was obtained, with a specified exercise price per share. Stockholder approval of this proposal confirms that the company obtained the necessary authorization for these warrants to become exercisable on the described terms.

FAQs about Tenon Medical, Inc. (TNONW)